Monday, March 25 - Wednesday, March 27
Vienna, Austria
March 25, 2019
President and CEO, Christopher J. Burns, Ph.D., will present the Company's novel, orally-bioavailable beta-lactamase inhibitor, VNRX-7145, during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting. The presentation entitled, “Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor (BLI) for highly resistant bacterial infections (“superbugs”)” is scheduled for Wednesday, April 3, 2019 at 10:35am ET in the Valencia Ballroom A at the Orange County Convention Center in Orlando, FL.
March 14, 2019
Recognition honors a CEO who has demonstrated visionary leadership and active participation to advance the life sciences and biotech industry.
February 28, 2019
The objective of this R01 grant is to provide tools that can facilitate therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae (CRE), multi-drug resistant (MDR) Acinetobacter baumannii and/or MDR Pseudomonas aeruginosa. This initiative will also support VenatoRx’s discovery programs targeting novel antibacterial agents.
February 06, 2019
Chief Business Officer, Tony Meehan, MBA, PhD, will present attendees with an overview of VenatoRx's pipeline and unique operating model on Monday, February 11, 2019 at 3:30pm ET in the Gramercy room at the New York Marriott Marquis.
January 03, 2019
The Antimicrobials Working Group (AWG) announced the addition of VenatoRx Pharmaceuticals to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 15 antimicrobial drug companies.
October 02, 2018
Posters for VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be presented on Friday, October 5, 2018 in S Poster Hall from 12:30pm to 1:45pm PT.
September 25, 2018
VenatoRx entered into an exclusive license agreement with Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company with operations based in China, to support the development, registration and commercialization of cefepime/VNRX-5133 in Greater China, South Korea and Southeast Asia for complicated urinary tract infections (cUTI), infections due to carbapenem resistant pathogens, and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
September 04, 2018
SMi Group is proud to announce the return of the Superbugs & Superdrugs USA conference to Iselin, NJ on the 12th and 13th November 2018.